An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2020
Price : $35 *
At a glance
- Drugs ADVM-022 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms OPTIC
- Sponsors Adverum Biotechnologies
- 12 Jan 2020 According to an Adverum Biotechnologies media release, the company expects to present longer-term data from the first cohort and second cohorts and clinical data from the third and fourth cohorts in the second half of 2020.
- 12 Jan 2020 According to an Adverum Biotechnologies media release, the company expects to complete patient dosing in the third cohort in first quarter of 2020.
- 12 Jan 2020 According to an Adverum Biotechnologies media release, results from first cohort were presented at the Atlantic Coast Retina Club and Macula 20/20.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History